Bank predicts double blockbuster status for Novo obesity drug next year

Novo Nordisk's weight loss drug Wegovy could be heading for double blockbuster status as soon as next year, according to an analysis by Danske Bank, which has almost doubled its previous expectations for the medicine.
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The obesity drug Wegovy, developed by Novo Nordisk, could reach double blockbuster status as soon as next year, estimates an analysis from Danske Bank, reports media PLX.AI.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading